Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof

A drug coating and restenosis technology, applied in the field of medical materials, can solve problems such as coating shedding, drug coating damage, and increased incidence of thrombus, and achieve the effects of improving adhesion, improving corrosion resistance, and avoiding shedding

Active Publication Date: 2012-09-12
DONGGUAN KEWEI MEDICAL INSTR
View PDF4 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] After the traditional drug-eluting stent is implanted in the human body, the drug release coating on the surface slowly and continuously releases the drug at the stenosis. However, the drug is easily metabolized directly by the blood vessel, the drug utilization rate is low, and the blood drug stability is low. Concentration duration is not ideal
In addition, the drug coating is prone to damage during the delivery and expansion of the stent, and once the drug coating is damaged, it is very likely to cause the coating to fall off in large pieces
Although current drug-eluting stents can significantly reduce restenosis after intraluminal artery angioplasty, the incidence of late stent thrombosis is increased, and the associated acute myocardial infarction and death increase

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1, a drug-coated stent for preventing vascular restenosis and its preparation method, the stent is a cobalt-chromium alloy, and the stent is covered with a nanoparticle coating, and the nanoparticle coating is rapamycin polymer Lactic-glycolic acid (RPM-PLGA) nanoparticle coating. The nanoparticle coating includes a drug carrier and a drug material, the drug carrier is polylactic-glycolic acid (PLGA), and the drug material is rapamycin (RPM), wherein the rapamycin and PLGA The mass ratio is 1:5.

[0022] The PLGA includes PLA and PGA, the molar ratio of PLA and PGA is 80:20, and the molecular weight of the PLGA is 40000.

[0023] The preparation method of the rapamycin polylactic-glycolic acid (RPM-PLGA) nanoparticle coating comprises the following steps:

[0024] ①. Firstly, the bracket is carved into a hollowed-out tubular body with a water jet engraving method.

[0025] ②. After the stent carving is completed, the PLGA is dissolved in dichloromethane to...

Embodiment 2

[0032] Embodiment 2, a drug-coated stent for preventing vascular restenosis and its preparation method, the stent is a cobalt-chromium alloy, the stent is covered with a nanoparticle coating, and the nanoparticle coating is paclitaxel polylactic acid-ethanol Acid nanoparticle coating. The nanoparticle coating includes a drug carrier and a drug material, the drug carrier is polylactic-glycolic acid (PLGA), and the drug material is paclitaxel, wherein the mass ratio of paclitaxel to PLGA is 1:6.

[0033] The PLGA includes PLA and PGA, the molar ratio of PLA and PGA is 80:20, and the molecular weight of the PLGA is 40000.

[0034] The preparation method of described paclitaxel polylactic acid-glycolic acid nano particle coating, comprises the steps:

[0035] ①. Firstly, the bracket is carved into a hollowed-out tubular body with a water jet engraving method.

[0036] ②. After the stent carving is completed, the PLGA is dissolved in dichloromethane to form a PLGA dichloromethane...

Embodiment 3

[0043] Embodiment 3, a drug-coated stent for preventing vascular restenosis and its preparation method, the stent is cobalt-chromium alloy, and the stent is coated with nanoparticle coating. The nanoparticle coating includes a drug carrier and a drug material, the drug carrier is polylactic-glycolic acid (PLGA), and the drug material is a mixture of rapamycin and paclitaxel, wherein the mixture of rapamycin and paclitaxel The mixing ratio is 1:1. The mass ratio of the drug material to the drug carrier is 1:6. The PLGA includes PLA and PGA, the molar ratio of PLA and PGA is 80:20, and the molecular weight of the PLGA is 40000.

[0044] The preparation method of described nano particle coating, comprises the steps:

[0045] ①. Firstly, the bracket is carved into a hollowed-out tubular body with a water jet engraving method.

[0046] ②. After the stent carving is completed, the PLGA is dissolved in dichloromethane to form a PLGA dichloromethane solution.

[0047] ③. Add rapam...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicament coating stent capable of preventing blood vessel restenosis and a preparation method thereof. The stent is coated with a PLGA (polylactic acid-glycollic acid) nano particle coating which comprises a medicament carrier and a medicament material; the medicament carrier is PLGA; and the medicament material is one or two of rapamycin or paclitaxel. The preparation method comprises the following steps of: dissolving PLGA with dichloromethane, adding the medicament material, dissolving fully, and performing ultrasonic emulsification by use of an ultrasonic cell disruptor under an ice bath condition so as to prepare a suspension; slowly adding a 2% PVA (Polyvinyl Alcohol) water solution into the suspension while performing magnetic stirring, and emulsifying the suspension again so as to prepare an emulsion; performing rotary evaporation on the emulsion under reduced pressure so as to enable dichloromethane to volatilize completely, so that a nano particular colloidal dispersion system is obtained; adding a 1% coupling agent into the system, and then soaking the stent into the system for 5 minutes, so as to prepare the coating stent; and freeze-drying the coating stent for 10 hours, and preserving the freeze-dried stent at the temperature of 4 DEG C.

Description

technical field [0001] The invention relates to a drug-coated stent in the field of medical materials, in particular to a drug-coated stent for preventing blood vessel restenosis and a preparation method thereof. Background technique [0002] Atherosclerosis is the main cause of ischemic heart disease caused by stenosis or obstruction of the lumen. Percutaneous transluminal angioplasty uses balloon inflation to dilate occluded or stenotic blood vessels to restore normal blood supply, which has been widely accepted and used in the treatment of coronary heart disease. Although the clinical effect of transluminal angioplasty has been satisfactory, its development is limited to a certain extent by its acute vascular occlusion and postoperative stenosis. [0003] In order to solve the problem of restenosis after transluminal angioplasty, domestic and foreign medical circles continue to innovate and explore. Researchers select polymers with good biocompatibility as media, mix dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/10A61L31/16
Inventor 杨树维冯舒捷唐云华丁伟峰
Owner DONGGUAN KEWEI MEDICAL INSTR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap